Prof J Gordon McVie MD, FRCP, FRCPS, FRCES, FMedSci, DSc (Hon)
Prof McVie is the Chairman of ORIL’s Board of Directors and Scientific Advisory Committee. Professor McVie was formerly Director General of the Cancer Research Campaign in the UK before it merged with the Imperial Cancer Research Foundation to form Cancer research UK, when he became co-Director General. Professor McVie is a leading world authority in the research and treatment of cancer, having trialled over 80 new chemical entities in the clinic.
Professor McVie is currently Senior Consultant at the Scientific Directorate within the European Institute of Oncology, Milan and Director of Cancer Intelligence, which provides advisory services to biotechnology and pharmaceutical companies, investors, the media and cancer patients. He is visiting professor at Glasgow University, honorary consultant in medical oncology at the Welsh Cancer Institute, Cardiff and Visiting Professor at Kings College London, UK.
Dr Philip A Marshall BSc(Hons), PhD, FRACI, CChem, MAICD
Dr Marshall is Chief Executive Officer and Executive Director who manages the corporate aspects of the Company, as well as the scientific and research programs. Dr Marshall’s skills and training cover synthetic organic and medicinal chemistry, pharmaceutical science, compliance and regulatory affairs and has strong familiarity with the mechanics of turning IP into a commercial business; he is co-inventor of two ORIL patents. In 1991 he founded his consultancy company, Pharmchem Technical Services Pty Ltd, which has provided independent advice to over 140 companies in Europe, South Africa, the Americas and throughout Asia-Pacific region. From 2004-06, he was also General Manager, Scientific Affairs at Sigma Pharmaceuticals (now Aspen) where he had executive responsibility over the company’s 6 Australian sites for R&D strategic planning, quality, regulatory affairs and technical due diligence in acquisitions.
Dr K Michael Wayte
Dr Wayte is Company Secretary and Executive Director. Dr Wayte was full time CEO of ORIL from 2003 to 2008 and is a major shareholder. He was diagnosed with bowel cancer in 1986, but after following a demanding and restrictive vegetarian diet with specific plant-based therapies he recovered and is alive and well today. As a result of his recovery he founded ORIL in 1993 with the objective of researching plant-based therapies for cancer.
Ms Elizabeth Wilkinson
Elizabeth is a Registered Nurse who has also completed a Post Graduate qualification in Pharmaceutical Science and Drug Development in 1997. She has worked in clinical research for 25 years and been directly involved in a multitude of therapeutic areas across over 150 Phase I to Phase IV trials, including 22 in oncology. She has significant international experience in overall project management of the clinical phases I to III of oncology drug development and has held management and executive management roles in both local and international Pharmaceutical and Clinical Research Organisations.
Elizabeth also has extensive experience in contract management, GCP compliance and audits, monitoring and training. In 2011 she co-founded Precise Quality Solutions Pty Ltd, a quality based clinical research consultancy business
Dr Michael J Story BE(Hons), PhD(Cantab)
Dr Story has over 35 years’ experience with the pharmaceutical industry including 13 years with FH Faulding & Co Limited (now Mayne), where he held a range of positions covering product development, marketing and manufacturing, before managing the R&D division for 6 years. He introduced new innovative technology and formulation skills to Faulding, which led to the highly successful international commercialisation of products based on these technologies. Dr Story founded his pharmaceutical consulting company, Story Pharmaceutics Pty Ltd, in 1991.
Dr Story has played a leading role in identifying and bringing the science of ORIL’s compounds to their current position. He is a co-inventor of two ORIL patents and maintains an ongoing input to the development of ORIL’s compounds.
